he field of oncology is entering a new and exciting period of discovery. For the first time, our understanding of tumor genetics and basic cell biology is leading to the rapid development of new therapies. Our ability to put these treatments to use, however, is dependent on our ability to study them in a scientific and controlled manner in clinical trials. North Carolina is a state with a very rich tradition of cancer research and patient care. We have 3 National Cancer Institute (NCI) Comprehensive Cancer Centers while 17 states have none at all. In addition, the state is the headquarters for the Southeastern Cancer Control Consortium (SCCC), the largest Community Clinical Oncology Program (CCOP) in the United States. The American Society of Clinical Oncology lists almost 600 physician members in the state and over 600 research studies are in place at nearly 250 sites. All in all, the state of North Carolina is clearly a leader in cancer care.Yet, even with this great potential, we still struggle with the problem of enrolling North Carolinians with cancer in clinical trials. It is estimated that between 2% to 5% of the adult cancer population enrolls in cancer clinical trials nationally, and this estimate is widely cited. 1 However, this reflects only enrollment in National Cancer Institute trials and does not include studies sponsored by the pharmaceutical industry or developed locally at the university centers. Others have estimated that if all other treatment trials were included, the rate might be twice this estimate, if not higher. It is difficult, however, to confirm any of these estimates because there is a lack of reproducible methodology for measuring enrollment, a fact that
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.